Commentary

Article

Fox Chase Cancer Center Welcomes Lorenzo Galluzzi

Fox Chase Cancer Center is pleased to announce the hiring of Lorenzo Galluzzi, PhD, as an Associate Professor with tenure in the Cancer Signaling and Microenvironment Research Program.

Lorenzo Galluzzi, PhD

Lorenzo Galluzzi, PhD

Fox Chase Cancer Center is pleased to announce the hiring of Lorenzo Galluzzi, PhD, as an Associate Professor with tenure in the Cancer Signaling and Microenvironment Research Program.

Prior to joining Fox Chase, Galluzzi was an Assistant Professor of cell biology in the Department of Radiation Oncology at the Weill Cornell Medical College in New York. His lab there focused on dissecting the links between adaptive stress responses of cancer cells and the activation of immune responses that target tumors during exposure to immunotherapy, chemotherapy, and radiation therapy.

“We are enormously excited to welcome Dr. Galluzzi to the Fox Chase and Temple family and look forward to working with him to further strengthen an already robust research program,” said Edna “Eti” Cukierman, PhD, Co-Leader of the Cancer Signaling and Microenvironment Research Program and Marvin & Concetta Greenberg Chair in Pancreatic Cancer Research.

Galluzzi is an Assistant Professor Adjunct with the Department of Dermatology at the Yale School of Medicine and a faculty member with graduate schools at several Italian universities, including the Graduate School of Biomedical Sciences and Biotechnology at the University of Ferrara, the Graduate School of Pharmacological Sciences at the University of Padova, and the Graduate School of Network Oncology and Precision Medicine at the University of Rome.

He is also Associate Director of the European Academy for Tumor Immunology and a founding member of the European Research Institute for Integrated Cellular Pathology.

Galluzzi received his doctoral degree from Paris-Sud University in 2008 and completed his postdoctoral training at the Gustave Roussy Comprehensive Cancer Center in Paris.

He has published over 500 scientific articles in peer-reviewed journals. Several outlets have named him a highly cited researcher worldwide from 2006 through 2023.

Galluzzi is Editor-in-Chief of the journals OncoImmunology, International Review of Cell and Molecular Biology, Methods in Cell Biology, and Molecular and Cellular Oncology. He is also a Consulting Editor for Pharmacological Research and an Associate Editor for Aging and Cell Death and Disease.

He is a member of the Spanish Group for Cancer Immune-Biotherapy, the Society for Immunotherapy of Cancer, the American Association for Cancer Research, the European Academy for Tumor Immunology, and the European Research Institute for Integrated Cellular Pathology.

Related Videos
Elizabeth Buchbinder, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Alec Watson, MD
3 experts are featured in this series.
Sangeetha Venugopal, MD, MS, discusses factors that inform JAK inhibitor selection in myelofibrosis.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.
2 experts in this video
2 experts in this video
Sagar D. Sardesai, MBBS